No Data
B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $51
B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating
Arrowhead Pharmaceuticals: Positioned for Growth With Strategic Partnerships and SiRNA Advancements
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating
Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...
